Founded in the year 1995, Oxford Biomedica Plc is a UK-based pharmaceutical company that specialises in gene and cell therapy. Headquartered in Oxford, the company is listed on the London Stock Exchange publicly and falls under the FTSE 250 index. The subsidiaries of the company are Oxxon Therapeutics Limited, Oxford Biomedica (UK) Limited and Biomedica Inc. Oxford Biomedica, along with its subsidiaries, has developed LentiVector platform, which is a lentiviral vector delivery system. LentiVector is used by the company to come forth with various products, including both in vivo and ex-vivo products. These products are developed both within the company as well as with partners via outsourcing activities. Oxford Biomedica was the first pharmaceutical company in the world to treat patients with in vivo lentiviral-based vectors and provide lifesaving treatments for serious diseases. These viral vectors are manufactured in three sites, which include the new manufacturing facility called OxBox, which is a world-class bioprocessing facility.
The partners of the company include major pharmaceutical companies, which include Novartis, SIO Gene Therapies, Santen, Boehringer Ingelheim, Beam Therapeutics, Imperial Innovations, the UK Cystic Fibrosis Gene Therapy Consortium, Juno Therapeutics/Bristol Myers Squibb, and Orchard Therapeutics. Amid the Covid-19 pandemic, in addition to these partnerships, the company has also signed an agreement with a globally leading vaccine producing company, AstraZeneca, to manufacture vaccines on a large scale and help save lives across the world. Oxford Biomedica aims to maintain a high-quality diversified portfolio which consists of a range of candidates involved in the production of cell and gene therapy products. Ophthalmology, liver diseases, CNS disorders, and oncology are the areas, which are covered by the product ranges in its portfolio.
Oxford Biomedica has a well-defined framework of corporate governance in place and aligns itself with the YK Corporate Governance Code 2018, which is revised by the Financial Reporting Council. It follows an ethical code of conduct for running its business operations due to its high stakes in affecting the lives of the patients.
It follows strict guidelines regarding clinical trials and has a controlled quality management system in place to ensure that the safety and quality standards are met. It upholds the culture of integrity, trust, transparency, and accountability, and prioritises the health and safety of its employs as well as the wider community.
The company aims to maximise the returns for all its stakeholders while minimising the risks and incorporates sustainability as an integral part of its business model. It has a comprehensive ESG framework and takes care of its social and environmental responsibilities in addition to its corporate responsibilities.
Oxford BioMedica PLC Windrush Court, Transport Way OXFORD OX4 6LT United Kingdom
+44 186 578 3000